Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS

Hepatobiliary and Pancreatic Diseases International

Volumn 12, Issue 2, 2013, Pages 204-209

  Duan, Yi Fan ^a,b   Li, Dong Feng ^b   Liu, Yan Hui ^b   Mei, Ping ^b   Qin, Yu Xuan ^b   Li, Liang Fang ^b   Lin, Qiu Xiong ^b   Li, Zi Jun ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

DAB2IP; KRAS type; Pancreatic cancer; Tumor suppressor

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; K RAS PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE K RAS; PANCREAS CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; WILCOXON SIGNED RANKS TEST; WILD TYPE;

EID: 84879267874     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(13)60032-6     Document Type: Article

References (26)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617.
2. Thomson BN, Banting SW, Gibbs P. Pancreatic cancer -current management. Aust Fam Physician 2006;35:212-217.
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
4. Morris JP 4th, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-695.
5. Iwashita S, Song SY. RasGAPs: a crucial regulator of extracellular stimuli for homeostasis of cellular functions. Mol Biosyst 2008;4:213-222.
6. Grewal T, Koese M, Tebar F, Enrich C. Differential Regulation of RasGAPs in Cancer. Genes Cancer 2011;2:288-297.
7. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta 2008;1786:178-187.
8. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002;1602:23-45.
9. Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, Allain B, Toccafondi M, Garbay C, et al. p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie 2009;91:320-328.
10. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
11. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-531.
12. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
13. Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 2009;3:757-769.
14. Zhang R, He X, Liu W, Lu M, Hsieh JT, Min W. AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 2003;111:1933-1943.
15. Xie D, Gore C, Zhou J, Pong RC, Zhang H, Yu L, et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA 2009; 106:19878-19883.
16. Chen H, Pong RC, Wang Z, Hsieh JT. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002;79:573-581.
17. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol 2006;25: 232-245.
18. Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA 2010;107:2485-2490.
19. Kong Z, Xie D, Boike T, Raghavan P, Burma S, Chen DJ, et al. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 2010;70:2829-2839.
20. Kong Z, Raghavan P, Xie D, Boike T, Burma S, Chen D, et al. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int J Radiat Oncol Biol Phys 2010;78:1210-1218.
21. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010;16:286-294.
22. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011;54:311-319.
23. Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang L, et al. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1117-1125.
24. Qiu GH, Xie H, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M, et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 2007;46: 655-663.
25. Kayahara M, Nakagawara H, Kitagawa H, Ohta T The nature of neural invasion by pancreatic cancer. Pancreas 2007;35:218-223.
26. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009; 115:3379-3391.